[Cutaneous Side Effects of EGFR Inhibitors--Appearance and Management]

摘要: Epidermal growth factor receptor (EGFR) inhibitors such as cetuximab, erlotinib, panitumumab und gefitinib, are increasingly used for the treatment of advanced, metastatic, or recurrent tumours like colorectal carcinoma, non-small cell lung cancer (NSCLC), squamous carcinoma head and neck (SCCHN) pancreatic cancer. For this reason common cutaneous side effects EGFR has become important: they stigmatize patient in daily life may lead to efficacious therapie being discontinued. Depending on particular inhibitor, an acneiform rash occurs 30 90 % patients. Severity, site, stage eruptions individual response influence decision given case. It follows forms acne rosacea, including topical systemic antibiotics their antimicrobial effect anti-inflammatory effect, sometimes combination with steroids. After several weeks additional sebostatic skin reactions, paronychia changes hair structure occur, calling individualized treatment. Only multidisciplinary collaboration between oncologists, radiotherapist dermatologists provide optimal care. This article gives overview occurrence latest options caused by inhibitors.